Question: Among high-risk patients with vascular disease treated with aspirin, is incomplete suppression of thromboxane generation associated with an increased risk of recurrent cardiovascular events? Population: Men and women $ 55 years of age who had a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes plus at least one other CV risk factor who participated in the HOPE trial which was a 2 3 2 factorial randomized controlled trial of ramipril and vitamin E. 1 Design and methods: Nested case-control study of the 5529 patients from the HOPE trial participants from Canada in whom a urine sample was collected at baseline. All samples were sent to a central laboratory and stored at -80°C. Only those patients who were taking aspirin were included. Cases were de ned as individuals who had a con rmed MI, stroke, or CV death after randomization. Control subjects were randomly selected from aspirin-treated patients who provided adequate urine samples but did not suffer MI, stroke or CV death after randomization. Cases and controls were matched according to sex and age (6 5 years) in a ratio of 1:1. Urine was thawed and assayed for 11-dehydro thromboxane B 2 levels using the Caymann Chemical immunoassay. Results: Among 488 cases and 488 matched controls, the odds of an MI, stroke or CV death increased with each increasing quartile of 11-dehydro thromboxane B 2 , with patients in the upper quartile having a 1.8 times higher risk than those in the lower quartile (OR = 1.8; 95% CI: 1.2-2.7, p = 0.009). Conclusion: Among aspirin-treated patents who have established vascular disease, urinary 11dehydro thromboxane B 2 predicts the future risk of MI and CV death, and may re ect 'aspirin resistance'.
Commentary
This is the rst study to demonstrate an association between aspirin resistance, de ned as a failure of suppression of thromboxane generation (and presumably thromboxaneinduced platelet aggregation), and cardiovascular risk. Aspirin is known to block platelet activation by inhibiting thromboxane A 2 synthesis, and is recommended for treatment of most people with CV disease. 2 However, it appears that up to 20% of people continue to generate thromboxane A 2 even while taking standard doses of aspirin.
Thromboxane B 2 is a stable metabolite of thromboxane A 2 , is a good surrogate marker, and is relatively simple to measure in the urine. This nested case-control analysis of the HOPE study demonstrates that a high concentration of thromboxane B 2 (. 33.8 ng/mmol) is a signi cant predictor of increasing CV risk among high-risk vascular patients who take aspirin. The relationship observed in this analysis was strong, graded, and was independent of other known correlates or confounders. This provides support for the hypothesis that incomplete suppression of thromboxane A 2 with aspirin in individuals with established vascular disease is associated with an increased number of CV events.
The ndings of this investigation are likely to be valid because no systematic bias in the selection of cases and controls is apparent. Selection of lower risk controls who could have lower thromboxane B 2 concentrations could lead to an overestimate of the odds increase in CV events, while selection of controls with many co-morbid conditions could lead to an underestimate of the odds increase in CV risk. Although it is possible that an increased thromboxane B 2 concentration among aspirin-treated patients re ects failure to suppress thromboxane B 2 production and hence platelet activation, it is possible that thromboxane levels may be associated with another risk marker or mediator which is associated with an increased chance of recurrent CV events. This issue can be resolved by replication of this nding in other large cohorts, or case-control studies. Furthermore, the generalizability of these results should be limited to patients with established vascular disease, as frequently risk predictors in the established disease population may not be risk predictors in non-diseased populations.
Vascular viewpoint rating:
· Nested case-control · Was the study valid? Yes · Are the results believable? Yes, and require con rmation in other study cohorts.
